Weight, Anthropometric and Metabolic Changes After Discontinuing Antiretroviral Therapy Containing Tenofovir Alafenamide (TAF) in People With Human Immunodeficiency Virus (HIV)

被引：11

作者：

Damas, Jose ^{[1
]}

Munting, Aline ^{[1
]}

Fellay, Jacques ^{[2
,3
]}

Haerry, David ^{[4
]}

Marzolini, Catia ^{[5
,6
]}

Tarr, Philip E. ^{[7
]}

Steffen, Ana ^{[8
]}

Braun, Dominique L. ^{[9
]}

Stoeckle, Marcel ^{[5
]}

Bernasconi, Enos ^{[10
,11
]}

Tshikung, Olivier Nawej ^{[12
]}

Fux, Christoph A. ^{[13
]}

Darling, Katharine E. A. ^{[1
]}

Beguelin, Charles ^{[14
]}

Wandeler, Gilles ^{[14
]}

Cavassini, Matthias ^{[1
]}

Surial, Bernard ^{[14
]}

机构：

[1] Univ Lausanne, Univ Hosp Lausanne, Infect Dis Serv, Rue Bugnon 46, CH-1011 Lausanne, Switzerland

[2] Ecole Polytech Fed Lausanne, Sch Life Sci, Lausanne, Switzerland

[3] Univ Hosp, Biomed Data Sci Ctr, Lausanne, Switzerland

[4] Chair Posit Council, Zurich, Switzerland

[5] Univ Basel, Univ Hosp Basel, Div Infect Dis & Hosp Epidemiol, Basel, Switzerland

[6] Univ Hosp Lausanne, Serv Clin Pharmacol, Lausanne, Switzerland

[7] Univ Basel, Univ Dept Med, Kantonsspital Bruderholz, Basel, Switzerland

[8] Cantonal Hosp St Gallen, Div Infect Dis, Infect Prevent & Travel Med, St Gallen, Switzerland

[9] Univ Zurich, Univ Hosp Zurich, Dept Infect Dis & Hosp Epidemiol, Zurich, Switzerland

[10] Univ Geneva, Div Infect Dis, Ente Osped Cantonale, Lugano, Switzerland

[11] Univ Southern Switzerland, Lugano, Switzerland

[12] Univ Geneva, Univ Hosp Geneva, Div Infect Dis, Geneva, Switzerland

[13] Cantonal Hosp Aarau, Div Infect Dis, Aarau, Switzerland

[14] Univ Bern, Bern Univ Hosp, Dept Infect Dis, Inselspital, Freiburgstr 20, CH-3010 Bern, Switzerland

来源：

CLINICAL INFECTIOUS DISEASES | 2024年 / 79卷 / 04期

基金：

瑞士国家科学基金会;

关键词：

antiretroviral therapy; tenofovir alafenamide; tenofovir disoproxil fumarate; weight; HIV; DISOPROXIL FUMARATE;

D O I：

10.1093/cid/ciae189

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Background Antiretroviral therapy (ART)-related weight gain is of particular concern in people with HIV (PWH). Although weight gain was observed among PWH receiving tenofovir alafenamide (TAF), little is known about the potential reversibility after TAF discontinuation. We evaluated weight and metabolic changes 12 months after TAF discontinuation in the Swiss HIV Cohort Study.Methods We included participants who received at least 6 months of TAF-containing ART between January 2016 and March 2023. Using multivariable mixed-effect models, changes in weight and lipid levels were compared between individuals who continued TAF and those who switched to one of the following TAF-free regimens: (1) tenofovir disoproxil fumarate (TDF)-based ART, (2) dolutegravir/lamivudine (DTG/3TC), or (3) long-acting cabotegravir/rilpivirine (CAB/RPV).Results Of 6555 participants (median age 54 years, 24.3% female, 13% Black), 5485 (83.7%) continued, and 1070 (16.3%) stopped TAF. Overall, discontinuing TAF was associated with an adjusted mean weight change of -0.54 kg (95% confidence interval [CI] -.98 to -.11) after 12 months. In stratified analyses, switching from TAF to TDF led to an adjusted mean weight decrease of -1.84 kg (95% CI -2.72 to -.97), and to a decrease in mean total cholesterol (-0.44 mmol/L) and triglycerides (-0.38 mmol/L) after 12 months. Switching from TAF-based ART to DTG/3TC (-0.17 kg, 95% CI -.82 to .48) or long-acting CAB/RPV (-0.64 kg, 95% CI -2.16 to .89) did not lead to reductions in weight.Conclusions Replacing TAF with TDF in PWH led to a decrease in body weight and an improved lipid profile within 1 year. Weight changes were not observed among individuals who switched to DTG/3TC or long-acting CAB/RPV. In the Swiss HIV Cohort Study, replacing tenofovir alafenamide (TAF) with tenofovir disoproxil fumarate (TDF) resulted in a -1.84 kg weight decrease within 1 year. No substantial weight changes were noted after switching from TAF to dolutegravir/lamivudine or cabotegravir/rilpivirine. Graphical Abstract

引用

页码：990 / 998

页数：9

共 50 条

[21] Weight and body mass index increase after switch from tenofovir disoproxil fumarate to tenofovir alafenamide fumarate-containing treatment in an antiretroviral therapy-experienced group
Lomiak, Michal
Stepnicki, Jan
Mikula, Tomasz
Wiercinska-Drapalo, Alicja
INTERNATIONAL JOURNAL OF STD & AIDS, 2021, 32 (06) : 570 - 577
[22] Transaminase changes in patients infected with human immunodeficiency virus after antiretroviral therapy
Najmi, Sheila N.
Katu, Sudirman
Daud, Nu'man A.
Bakri, Syakib
Kasim, Hasyim
Pango, Faridin H.
Seweng, Arifin
GAZZETTA MEDICA ITALIANA ARCHIVIO PER LE SCIENZE MEDICHE, 2023, 182 (09) : 502 - 508
[23] Impact of tenofovir-containing antiretroviral therapy on chronic hepatitis B in a cohort co-infected with human immunodeficiency virus
Stephan, C
Berger, A
Carlebach, A
Lutz, T
Bickel, M
Klauke, S
Staszewski, S
Stuermer, M
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2005, 56 (06) : 1087 - 1093
[24] Metabolic effects of switching to Biktarvy (B/F/TAF) in patients with HIV-1 treated with antiretroviral regimens that do not include tenofovir disoproxil fumarate (TDF) or tenofovir alafenamide (TAF): The Metabic study
Busca-Arenzana, C.
Ortega-Gonzalez, D.
Diaz-Almiron, M.
Montes, M. L.
Martin-Carbonero, Luz
Mican, R.
Montejano, R.
Ramos-Ruperto, L.
Valencia, Eulalia
Delgado-Hierro, Ana
Bernardino, Jose I.
HIV MEDICINE, 2024, 25 (09) : 1030 - 1039
[25] Weight change with antiretroviral switch from integrase inhibitor or tenofovir alafenamide-based to Doravirine-Based regimens in people with HIV
Kousari, Arianna E.
Wilson, Melissa P.
Hawkins, Kellie L.
Bandali, Mohamed Mehdi
Henao-Martinez, Andres F.
Gardner, Edward M.
Erlandson, Kristine M.
HIV RESEARCH & CLINICAL PRACTICE, 2024, 25 (01)
[26] Brief communication: comparison of changes in metabolic parameters following antiretrovial therapy with treatment regimens containing tenofovir alafenamide and tenofovir disoproxil fumarate
Mirmoezzi, Hamed
Koochak, Hamid Emadi
Manshadi, Seyed Ali Dehghan
Hasannezhad, Malihe
Seyedalinaghi, Seyedahmad
Semnani, Kiavash
Abbasian, Ladan
Ghaderkhani, Sara
AIDS RESEARCH AND THERAPY, 2025, 22 (01):
[27] Blood immune cells from people with HIV on antiviral regimens that contain tenofovir alafenamide (TAF) and tenofovir disoproxil fumarate (TDF) have differential metabolic signatures
Ritou, Eleni
Satta, Sandro
Petcherski, Anton
Daskou, Maria
Sharma, Madhav
Vasilopoulos, Hariclea
Murakami, Eisuke
Shirihai, Orian S.
Kelesidis, Theodoros
METABOLISM-CLINICAL AND EXPERIMENTAL, 2023, 141
[28] Tenofovir-Containing Antiretroviral Therapy and Clinical Outcomes of SARS-CoV-2 Infection in People Living with HIV
Rombini, Maria F.
Cecchini, Diego
Menendez, Sofia Diana
Calanni, Liliana
Cuini, Rosana
Obieta, Elena
Greco, Maria M.
Morales, Fabricio
Morganti, Laura
Migazzi, Claudia
El Kozah, Yasmin
Parenti, Pablo
Cassetti, Isabel
VIRUSES-BASEL, 2023, 15 (05):
[29] Effect of anthropometric and sociodemographic variables on physical activity levels of people living with human immunodeficiency virus/acquired immunodeficiency syndrome on highly active antiretroviral therapy
Anikpe, Jane Nwanneka
Chukwu, Aroh Joseph
Edem, Ekom Ndifreke
Elahmar, Adel A. E.
Sinha, Sohini
Arome, David
TZU CHI MEDICAL JOURNAL, 2023, 35 (02): : 200 - 204
[30] Young age is a key determinant of body weight gain after switching from tenofovir disoproxil fumarate to tenofovir alafenamide in Japanese people living with HIV
Sekiya, Ryoko
Muramatsu, Takashi
Ichiki, Akito
Chikasawa, Yushi
Bingo, Masato
Yotsumoto, Mihoko
Hagiwara, Takeshi
Amano, Kagehiro
Kinai, Ei
JOURNAL OF INFECTION AND CHEMOTHERAPY, 2023, 29 (02) : 171 - 178

← 1 2 3 4 5 →